CONSTITUENT REPORT
Limonene
Limonene is one of the AromaForge archive's most common monoterpene hydrocarbons and is especially dominant in citrus peel oils, while also appearing in eucalyptus, mint, conifer, resin, and spice profiles. The evidence base is unusually broad for an aroma constituent: identity and occurrence are very strong, preclinical literature repeatedly reports inflammation- and oxidative-stress-related effects in cell and animal models, and human-relevant safety literature consistently warns that limonene becomes more irritating and sensitizing after air oxidation. For archive use, limonene is best described as a high-frequency aroma and formulation constituent with meaningful preclinical research but important oxidation-dependent skin-allergy handling.
Chemical identity and composition
PubChem lists limonene as C10H16 with InChIKey XMGQYMWWDOXHJM-UHFFFAOYSA-N. NCBI's IARC monograph notes that limonene occurs as d/R and l/S enantiomers as well as dl mixtures including the racemate often called dipentene. In the local archive, generic limonene is used for many oils, while some records separately track enantiomer-specific material such as d-limonene in sweet orange and l-limonene in spearmint.
Aroma and practical use
- Use the recorded citrus, orange-peel, fresh, sweet, terpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
raw2647 inflammation model
A PubMed-listed macrophage study reported that D-limonene suppressed LPS-induced nitric oxide, prostaglandin E2, and cytokine production, providing a direct constituent-level anti-inflammatory signal in vitro.
Measured: nitric oxide, prostaglandin E2, and pro-inflammatory cytokine output
This experimental finding does not establish benefit, dose or safety in people using this blend.
rat colitis model
A 2013 rat study concluded that oral d-limonene showed significant anti-inflammatory effects in experimental colitis and reported protective effects on the intestinal barrier and inflammatory response.
Measured: colon inflammation, barrier function, and tissue injury
This experimental finding does not establish benefit, dose or safety in people using this blend.
oxidation and irritation
A human patch-test study reported that non-oxidized limonene was non-irritating at tested concentrations, whereas oxidized R-limonene became more irritating after air exposure.
Measured: irritation differences between oxidized and non-oxidized limonene
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
hydroperoxide contact allergy prevalence
A US patch-test study found measurable contact-allergy prevalence to hydroperoxides of d-limonene, reinforcing that the main practical safety concern is oxidation-product sensitization rather than fresh limonene itself.
Measured: contact allergy prevalence to hydroperoxides of d-limonene
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The strongest practical safety theme is oxidation: multiple human and review sources report that limonene oxidation products, especially hydroperoxides, are more irritating and sensitizing than fresh limonene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
A 2013 toxicology review states that oxidation products or metabolites of d-limonene were shown to act as skin irritants in animals and humans.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No phototoxic restriction specific to limonene itself was verified in this pass; oxidation-driven fragrance allergy is the more relevant archive concern.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
alpha-PineneNeutral record
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · antioxidant
No source citation attached.
Read alpha-Pinene report →LinaloolNeutral record
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
human clinical · effect
No source citation attached.
Read Linalool report →SabineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Sabinene report →alpha-TerpineolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
human clinical · effect
No source citation attached.
Read alpha-Terpineol report →1,8-cineoleOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read 1,8-cineole report →(E)-CaryophylleneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
human clinical · effect
No source citation attached.
Read (E)-Caryophyllene report →geranialAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read geranial report →Linalyl acetateAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Linalyl acetate report →beta-PineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read beta-Pinene report →L-carvoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read L-carvone report →CarvoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Carvone report →NeralAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Neral report →citralAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read citral report →gamma-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · antioxidant
No source citation attached.
Read gamma-Terpinene report →p-CymeneOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read p-Cymene report →CampheneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Camphene report →alpha-PineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
animal · effect
No source citation attached.
Read alpha-Pinene report →beta-EudesmolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vivo nonhuman · effect
No source citation attached.
Read beta-Eudesmol report →CarvacrolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Carvacrol report →EugenolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · whole_oil
No source citation attached.
Read Eugenol report →ThymolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Thymol report →trans-AnetholeAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · whole_oil
No source citation attached.
Read trans-Anethole report →How the effects were investigated
suppression of lps induced inflammatory mediator production
A macrophage-model study reported that D-limonene reduced LPS-induced nitric oxide and prostaglandin E2 production, supporting a commonly cited inflammation-modulating mechanism signal for limonene-class materials.
This experimental finding does not establish benefit, dose or safety in people using this blend.
reduction of colitis associated inflammatory signaling
In a rat colitis model, oral d-limonene was reported to reduce inflammatory damage markers including MPO activity, cytokine-related readouts, and colon injury features, which supports the broader anti-inflammatory preclinical theme without implying clinical efficacy.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- The benefit-facing limonene literature is still mostly cell, animal, or review evidence rather than robust constituent-specific human efficacy trials.
- This archive record groups limonene broadly, but some sources and oils distinguish d-limonene, l-limonene, or racemic limonene more precisely than others.
- No standalone public IFRA-style leave-on maximum for isolated limonene was verified in this pass.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.